Gliclazide is a sulfonylurea derivative of the II generation, an oral hypoglycemic agent that stimulates insulin secretion by pancreatic beta cells.
Release form and composition
Dosage form of the drug - tablets containing:
- 80 mg of gliclazide;
- Auxiliary components: sodium starch glycolate, lactose, calcium stearate, microcrystalline cellulose, colloidal silicon dioxide, hydroxypropylcellulose.
Implemented tablets Gliclazide 60 pcs. in a package (10 pcs. in one blister) and 120 pcs. in plastic cans.
Also, the drug is available in the form of tablets with a modified release of Gliclazide MB, containing:
- 30 mg gliclazide;
- Additional components: hypromellose, calcium stearate, colloidal silicon dioxide, lactose monohydrate, talc.
These tablets are sold in 10 pieces. in blister packs (1, 2, 3 or 6 pieces per pack), as well as in plastic cans of 10 or 20 tablets.
Indications for use
According to the instructions to Gliclazide, the indication for the use of the drug is diabetes of the second type, including the initial manifestations of diabetic microangiopathy.
As part of complex therapy (in combination with other sulfonylurea derivatives), Gliclazide is prescribed for the prevention of microcirculation disorders.
The use of Gliclazide is contraindicated in:
- Diabetic precoma and coma;
- Diabetes mellitus type one;
- Diabetic ketoacidosis;
- Impaired renal / hepatic function;
- Infectious diseases that are accompanied by a violation of food absorption and the development of hypoglycemia;
- Intestinal obstruction;
- Hyperosmolar coma;
- Paresis of the stomach.
In addition, the drug should not be taken:
- In case of burns, serious injuries, extensive surgical operations and other conditions that require immediate insulin therapy;
- In case of hypersensitivity to gliclazide, any auxiliary component, to sulfonylurea derivatives and sulfonamides;
- During pregnancy;
- If necessary, the simultaneous use of imidazole derivatives (including miconazole);
- Women who breastfeed.
Careful medical observation during the period of Gliclazide and individual dose selection is required for patients with impaired thyroid function, with febrile syndrome, as well as to persons who abuse alcohol.
Dosing and Administration
The specific dosage of the drug sets the attending physician. This takes into account the patient's age, the presence and severity of the clinical symptoms of the disease and the necessary level of fasting glucose and 2 hours after a meal.
According to the instructions to Gliclazide, the initial daily dose is 80 mg, the average is 160 mg, the maximum allowable is 320 mg. The drug should be taken twice a day for 30-60 minutes before a meal.
The initial dose of Gliclazide MB is 30 mg. With a lack of therapeutic effect about once every 2 weeks, the dosage can be gradually increased to a maximum daily dose of 120 mg (Table 4). Modified-release tablets should be taken once a day during breakfast.
When using Gliclazide, the following side effects may occur:
- From the hemopoietic system: thrombocytopenia, leukopenia, anemia;
- On the part of the digestive system: dyspepsia (most often it is nausea, heaviness in epigastria, diarrhea), anorexia (its severity decreases when taking the drug during a meal), abnormal liver function (including cholestatic jaundice and increased activity of hepatic transaminases) ;
- Allergic reactions: urticaria, maculopapular rash, itching;
If you violate the dosing regimen of Gliclazide and observe an inadequate diet, hypoglycemia may develop (a decrease in the glucose level below 3.5 mmol / l and peripheral blood below the norm). This condition can manifest symptoms such as headache, severe weakness, hunger and fatigue, increased sweating, anxiety, irritability, inattention, inability to concentrate, aggression, blurred vision, depression, delayed reaction, helplessness, sensory disturbances, tremor, aphasia , hypersomnia, dizziness, convulsions, delirium, loss of consciousness, shallow breathing, bradycardia, loss of self-control.
Overdose of the drug in most cases leads to the development of hypoglycemia, up to hypoglycemic coma. If a person who has taken an overdose of Gliclazide is conscious, he should immediately be given a solution of sugar or dextrose (orally). If the patient is unconscious, he is shown in / in the introduction of a 40% dextrose solution, in / m the introduction of glucagon. After the restoration of consciousness in order to avoid the re-development of hypoglycemia, the patient should be given food rich in easily digestible carbohydrates.
Drug treatment must be supplemented with a low-calorie diet with a low carbohydrate content.
During the period of Gliclazide, you should regularly check the level of fasting glucose and after meals.
If necessary, Gliclazide MB can be used in combination with other hypoglycemic agents - alpha-glucosidase inhibitors, insulin or biguanides.
Structural analogues of Gliclazide (i.e. by the active substance) are Glidiab, Glicclade, Glyukostabil, Diabetalong, Gliclazid-AKOS, Diabeton MV, Diabinax, Diabefarm MV, Diabefarm, Diatica
The following drugs are characterized by a similar mechanism of action and to the same pharmacological subgroup: Meglimid, Glemeune, akhmetr, and akhastrov, Glybenezl Retard, Glibenclamide, Glibex, Glimepirid, Glemaz, Glidanil, Glurenorm, Glimidstada, Glumedeks, Movogleks, Glidanil, Glyurenem, Glimidstada, Glyumedeks, Movogleks, Glymedanil, Glyurenem, Glimidstad, Glyumedeks, Movogleks, Glymedanil, Glymerans, Glymidestad, Glyumedeks, Movogleks;
Terms and conditions of storage
Gliclazide is a drug that is dispensed from pharmacies by prescription.
Store the medicine at a temperature up to 25 ºC. Shelf life of tablets is 2 years.